Resistance to cancer therapy continues to be a major limitation for the successful treatment of cancer. There are many published studies on therapy resistance in breast and prostate cancers; however, there are current...Resistance to cancer therapy continues to be a major limitation for the successful treatment of cancer. There are many published studies on therapy resistance in breast and prostate cancers; however, there are currently no data on molecular markers associated with resistance. The conflicting data were reported regarding the AKT/m-TOR signaling pathway components as markers predicting resistance. The AKT/m-TOR signaling pathway is involved in the development of many human cancers; its activation is related to cell proliferation, angiogenesis, apoptosis, as well as to therapy resistance. Molecular alterations in the AKT/m-TOR signaling pathway provide a platform to identify universal markers associated with the development of resistance to cancer therapy.展开更多
目的探讨经直肠超声(transrectal ultrasound,TRUS)引导下前列腺穿刺活检结合血清前列腺特异抗原(prostate specific antigen,PSA)在诊断前列腺癌(prostate cancer,PCA)中的临床意义。方法经直肠超声检查联合超声引导下穿刺病理证实的...目的探讨经直肠超声(transrectal ultrasound,TRUS)引导下前列腺穿刺活检结合血清前列腺特异抗原(prostate specific antigen,PSA)在诊断前列腺癌(prostate cancer,PCA)中的临床意义。方法经直肠超声检查联合超声引导下穿刺病理证实的前列腺癌患者62例,病例来源于2005年1月至2014年8月在本院超声诊断科检查的3 874例前列腺疾病门诊患者,年龄(68.5±13.5)岁,分析前列腺癌经直肠超声图像特征分型及其PSA值的分布情况。结果前列腺癌的经直肠超声图像特征可分为隐匿型、结节型、弥漫浸润型及弥漫浸润伴结节型,且弥漫浸润型和弥漫浸润伴结节型各自与前两种(隐匿型和结节型)之间的PSA值差异有统计学意义(P<0.01),而隐匿型和结节型之间以及弥漫浸润型和弥漫浸润伴结节型组别之间的PSA值差异无统计学意义(P>0.05)。结论血清PSA值结合TRUS引导下前列腺穿刺活检,对于前列腺癌(尤其是隐匿性和弥漫浸润型前列腺癌)具有重要诊断价值。展开更多
文摘Resistance to cancer therapy continues to be a major limitation for the successful treatment of cancer. There are many published studies on therapy resistance in breast and prostate cancers; however, there are currently no data on molecular markers associated with resistance. The conflicting data were reported regarding the AKT/m-TOR signaling pathway components as markers predicting resistance. The AKT/m-TOR signaling pathway is involved in the development of many human cancers; its activation is related to cell proliferation, angiogenesis, apoptosis, as well as to therapy resistance. Molecular alterations in the AKT/m-TOR signaling pathway provide a platform to identify universal markers associated with the development of resistance to cancer therapy.
